Browse diseases

… (89.7%) met ACR/EULAR 2013 criteria and 6 met VEDOSS criteria. Limited cutaneous scleroderma (63.8) was the predominant subtype and 65.5% reported esophagea…

…ve shown that S100A4 is implicated in skin and lung fibrosis in systemic sclerosis (SSc).Previous work [Denton et al, 2023] demonstrated that reco…

… action through BAG3 pathway inhibition (figure 1E).Conclusions SSc skin fibroblasts exhibit constitutive BAG3 overexpression coupl…

…ysis, we show significant differences in cell abundance between SSc and HC in the colon, that also differ between gastric and colon…

…ients with fibrosis by imaging (p < 0.001) and prior/coexistent cancer (p=0.01), shown in table 1. As of last follow-up, the significa…

…inal tract is the second most commonly affected organ system in systemic sclerosis (SSc). Any segment of the gastrointestinal tract—from the oral …

…re.Material and Methods Data were drawn from Adelphi Real World SSc Disease Specific Programme™, a cross-sectional survey of rheuma…

…Introduction Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by vasculopathy,…

…n Esophageal dysmotility is a frequent and disabling feature of systemic sclerosis (SSc), often presenting with dysphagia, heartburn or reflux. Hi…

…tial lung disease (ILD).Material and Methods The Western Sweden Systemic Sclerosis Project (WESST) is a longitudinal cohort study of SSc patients …

…ifying those VEDOSS lipid signatures linked with progression to SSc.…

… for its immunomodulatory properties and is often prescribed in systemic sclerosis (SSc), despite the lack of confirmation of its efficacy in randomized…